How Analyst Revisions Are Rewriting The Story For Plus Therapeutics (PSTV) [Yahoo! Finance]
Plus Therapeutics (NASDAQ:PSTV) is now covered by analysts at Lake Street Capital. They set a "buy" rating and a $2.00 price target on the stock.
Plus Therapeutics (NASDAQ:PSTV) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript [Seeking Alpha]
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization [Yahoo! Finance]